Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics develops therapies intended to address underlying causes of heart disease, with a clinical-stage pipeline led by TN-201 and TN-401 gene therapies. TN-201 is an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Company news commonly covers clinical data from the MyPEAK-1 and RIDGE-1 studies, financial results, cardiovascular research collaborations, and preclinical work supporting TN-301, a highly selective HDAC6 inhibitor studied for heart failure and related cardio/muscular disease. Updates also reference Tenaya’s target identification and validation capabilities, including iPSC-derived cardiomyocytes, engineered heart tissue models and in vivo disease models.
Tenaya Therapeutics (NASDAQ:TNYA) reported positive interim data from Cohorts 1 and 2 of the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for PKP2-associated ARVC.
All six treated adults showed meaningful PVC burden reductions (mean 64%) with TN-401 well tolerated at 3E13 and 6E13 vg/kg and supported by biopsy evidence of cardiac transduction. TN-401 also received EMA PRIME designation.
Tenaya Therapeutics (NASDAQ: TNYA) reported Q1 2026 results and a business update on May 6, 2026. Cash and cash equivalents were $80.9M as of March 31, 2026, and Tenaya expects funding into the second half of 2027 including a $10.0M upfront from an Alnylam collaboration. The company highlighted upcoming clinical readouts for TN-201 and TN-401, preclinical TN-301 DMD data, FDA Rare Pediatric and Orphan designations for TN-301, and expanded research with Alnylam with milestones up to $1.1B.
Tenaya Therapeutics (NASDAQ: TNYA) announced acceptance of multiple abstracts for ASGCT 2026, including a late-breaking oral presentation with new clinical data from both dose cohorts of the RIDGE-1 Phase 1b/2 trial of TN-401 for PKP2-associated ARVC. The presentation will include one-year Cohort 1 results and early Cohort 2 safety, biopsy and efficacy data on May 15, 2026. Tenaya will also present two posters and plans a webcast conference call to review RIDGE-1 data.
Tenaya Therapeutics (NASDAQ: TNYA) reported Q4 and full-year 2025 results, highlighted early clinical readouts for lead gene therapies TN-201 and TN-401, preclinical TN-301 data in DMD models, a multi-target research collaboration with Alnylam, and a December public offering raising net proceeds of $55.8M.
The company reported cash and marketable securities of $100.5M at year-end and expects resources plus an anticipated Alnylam upfront payment to fund operations into the second half of 2027.
Tenaya Therapeutics (NASDAQ: TNYA) presented preclinical data at MDA 2026 showing its selective HDAC6 inhibitor TN-301 improved muscle performance and corrected DMD cardiomyopathy drivers in vitro and in vivo. TN-301 restored mdx mouse muscle function to wild-type levels at 3 mg/kg and corrected human DMD iPSC-cardiomyocyte defects. A Phase 1 in healthy adults showed TN-301 was generally well tolerated without serious adverse events or dose-limiting toxicities. Tenaya plans to advance TN-301 toward Phase 2 clinical development, with HFpEF and DMD among prioritized indications.
Tenaya Therapeutics (NASDAQ: TNYA) entered a research collaboration with Alnylam (NASDAQ: ALNY) on March 5, 2026 to identify and validate up to 15 gene targets for cardiovascular disease.
Tenaya will receive up to $10 million upfront plus reimbursed costs over a two-year validation term and may receive up to $1.13 billion in development and commercial milestone payments if targets lead to approved therapeutics; Alnylam will handle development and commercialization.
Tenaya Therapeutics (NASDAQ: TNYA) will present at the Leerink Partners Global Healthcare Conference in Miami from March 9-11, 2026. CEO Faraz Ali will join a fireside chat on March 9, 2026 at 1:00 pm ET. A live webcast will stream via the company Investors site, with an archived replay available for approximately 30 days.
Tenaya Therapeutics (NASDAQ: TNYA) outlined 2026 priorities and clinical milestones for its two lead gene therapies for inherited cardiomyopathies. The company expects interim and longer-term MyPEAK-1 (TN-201 for MYBPC3 HCM) and RIDGE-1 (TN-401 for PKP2 ARVC) data in H1 and H2 2026, plans to pursue regulatory alignment for pivotal studies during 2026, and reported raising $60 million in Dec 2025 to supplement a $56.3 million Q3 2025 cash balance, collectively expected to fund operations through mid-2027.
Earlier interim data showed tolerability, increased MyBP-C protein, biopsy transduction, and early clinical improvements in small cohorts.
Tenaya Therapeutics (Nasdaq: TNYA) priced an underwritten public offering of 50,000,000 units at $1.20 per unit for gross proceeds of $60.0 million before discounts, commissions and expenses. Each unit consists of one share of common stock and a warrant to purchase one share at an exercise price of $1.50; warrants expire five years from issuance and are immediately exercisable.
The company intends to use net proceeds to fund development of clinical and early-stage candidates, particularly TN-201 and TN-401, and for working capital. Closing is expected on or about December 15, 2025, subject to customary conditions.
Tenaya Therapeutics (Nasdaq: TNYA) announced on December 11, 2025 that it intends to offer and sell units consisting of common stock and warrants to purchase common stock, and may offer pre-funded units (pre-funded warrants plus warrants) to certain investors.
All securities will be sold by Tenaya, the pre-funded warrants (if used) will be immediately exercisable and will not expire, and the offering is subject to market conditions with no assurance as to completion, size, or terms. Leerink Partners and Piper Sandler are joint bookrunning managers. The offering will be conducted under a previously declared effective Form S-3 and a preliminary prospectus supplement will be filed with the SEC.